文献速递心力衰竭与心肌病

肺至心纳米微球肽促进猪慢性心衰模型心脏恢复

Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure.
PubMed 文献 · J Am Coll Cardiol · 2024-01-01

研究在起搏诱导的HFrEF小型猪模型中,评估可吸入肺至心纳米微球技术(LungToHeartNIM)递送模拟肽(MP)的安全性与疗效。结果显示吸入dpCaP-MP使LVEF绝对值提高17%±6%,逆转心脏重构并减轻肺淤血,且耐受良好无不良事件。

要点

  • 吸入dpCaP-MP可绝对提高LVEF 17%±6%,并逆转心脏重构、减轻肺淤血。
  • 该治疗耐受良好,未发生不良事件。
  • LungToHeartNIM可实现治疗性肽向病变心脏的有效递送。

核心结论

  • LungToHeartNIM递送LTCC调节模拟肽整体耐受良好,并展现对HFrEF的有益效应,提示其可能成为HFrEF的治疗策略。
  • 该技术实现了治疗性肽向病变心脏的有效递送。

研究设计与样本

  • 在Göttingen小型猪中通过6周快速起搏诱导HFrEF,第4周起随机开始治疗。
  • 在LVEF 30%±8%的明显HFrEF背景下,动物吸入甘露醇基质微球包载MP的磷酸钙纳米粒干粉(dpCaP-MP)或仅吸入LungToHeartNIM(不含MP的dpCaP)。
  • 采用超声心动图、有创血流动力学和生物标志物评估疗效。

主要发现

  • dpCaP-MP吸入使治疗期间LVEF绝对值提高17%±6%。
  • 治疗逆转心脏重构并减轻肺淤血。
  • 在治疗HF动物的离体心肌纤维中重现了该效应。
  • 治疗耐受良好,未发生不良事件。

临床怎么用

  • 为HFrEF提供了一种可吸入、心脏靶向的肽类递送策略。
  • LTCC转运调节可能是HFrEF的潜在治疗靶点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The lack of disease-modifying drugs is one of the major unmet needs in patients with heart failure (HF). Peptides are highly selective molecules with the potential to act directly on cardiomyocytes. However, a strategy for effective delivery of therapeutics to the heart is lacking. OBJECTIVES: In this study, the authors sought to assess tolerability and efficacy of an inhalable lung-to-heart nano-in-micro technology (LungToHeartNIM) for cardiac-specific targeting of a mimetic peptide (MP), a first-in-class for modulating impaired L-type calcium channel (LTCC) trafficking, in a clinically relevant porcine model of HF. METHODS: Heart failure with reduced ejection fraction (HFrEF) was induced in Göttingen minipigs by means of tachypacing over 6 weeks. In a setting of overt HFrEF (left ventricular ejection fraction [LVEF] 30% ± 8%), animals were randomized and treatment was started after 4 weeks of tachypacing. HFrEF animals inhaled either a dry powder composed of mannitol-based microparticles embedding biocompatible MP-loaded calcium phosphate nanoparticles (dpCaP-MP) or the LungToHeartNIM only (dpCaP without MP). Efficacy was evaluated with the use of echocardiography, invasive hemodynamics, and biomarker assessment. RESULTS: DpCaP-MP inhalation restored systolic function, as shown by an absolute LVEF increase over the treatment period of 17% ± 6%, while reversing cardiac remodeling and reducing pulmonary congestion. The effect was recapitulated ex vivo in cardiac myofibrils from treated HF animals. The treatment was well tolerated, and no adverse events occurred. CONCLUSIONS: The overall tolerability of LungToHeartNIM along with the beneficial effects of the LTCC modulator point toward a game-changing treatment for HFrEF patients, also demonstrating the effective delivery of a therapeutic peptide to the diseased heart.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Alogna, Berboth, Faragli, et al. Lung-to-Heart Nano-in-Micro Peptide Promotes Cardiac Recovery in a Pig Model of Chronic Heart Failure. J Am Coll Cardiol. 2024. PMID: 38171710. doi:10.1016/j.jacc.2023.10.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。